Thumbnail
Access Restriction
Open

Author Sambi, Manpreet ♦ Bagheri, Leila ♦ Szewczuk, Myron R. ♦ {"id":"U30417842","contrib_type":"Guest Editor","surname":"Gupta","given-names":"Subash C.","orcid":"http://orcid.org/0000-0001-8471-5481"}
Source Hindawi
Content type Text
Publisher Hindawi
File Format PDF
Copyright Year ©2019
Language English
Abstract Cancer immunotherapy is a promising innovative treatment for many forms of cancer, particularly melanoma. Although immunotherapy has been shown to be efficacious, patient response rates vary and, more often than not, only a small subset of the patients within a large cohort respond favourably to the treatment. This issue is particularly concerning and becomes a challenge of immunotherapy to improve the effectiveness and patient response rates. Here, we review the specific types of available immunotherapy options, their proposed mechanism(s) of action, and the reasons why the patient response to this treatment is variable. The potential favourable options to improve response rates to immunotherapy will be discussed with an emphasis on adopting a multimodal approach on the novel role that the gut microbiota may play in modulating the efficacy of cancer immunotherapy.
ISSN 16878450
Learning Resource Type Article
Publisher Date 2019-02-28
Rights License This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
e-ISSN 16878469
Journal Journal of Oncology
Volume Number 2019
Page Count 12


Open content in new tab

   Open content in new tab